- Zimmer Biomet (ZBH) Valuation Check After Announcing Expanded US$1b Share Repurchase Plan
May 15, 2026
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Zimmer Biomet Holdings (ZBH) has drawn fresh attention after announcing plans to repurchase up to US$1b of its common stock in fiscal 2026, representing a US$250m increase under its existing authorization.
See our latest analysis for Zimmer Biomet Holdings.
Despite the enlarged 2026 repurchase plans and upcoming appearance at the Bank of America Global Healthcare Conference, the stock’s recent momentum has been weak, with the 30 day share price return down 14.37% and the 1 year total shareholder return declining 13.66%, extending a 5 year total shareholder return decline of 46.77%.
If you are weighing other opportunities in medical technology and related areas, it could be a good time to review 34 healthcare AI stocks.
With the stock down sharply over multiple time frames, yet trading at a reported 59% discount to one intrinsic value estimate and below the average analyst price target, you have to ask: is this a genuine opportunity, or is the market already reflecting Zimmer Biomet’s future growth?
Most Popular Narrative: 19.7% Undervalued
Zimmer Biomet’s most followed narrative pegs fair value at $102.95, above the last close at $82.65, framing the current price as a sizable discount.
The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is associated with increased adoption of premium offerings, enabling margin expansion due to product mix and supporting recurring revenues through connected care ecosystems, which is viewed as supportive of higher net margins and earnings predictability.
Read the complete narrative.
Want to see what kind of revenue mix, margin profile, and long term earnings path are used to support that higher fair value estimate? The full narrative lays out the projections, the timing, and how much the model attributes to repurchases versus operating progress.
Result: Fair Value of $102.95 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on Zimmer Biomet executing cleanly on U.S. commercial changes and major acquisitions, as well as managing pricing pressure and regulatory timing around new robotics platforms.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Next Steps
With both risks and rewards in play, are you comfortable taking the market’s view at face value, or do you want to pressure test it yourself using the 3 key rewards and 2 important warning signs?
Story Continues
Looking for more investment ideas?
If Zimmer Biomet has your attention, do not stop here. Broaden your watchlist with fresh stock ideas that could suit different goals and risk levels.
Target potential mispricing by scanning companies that screen as quality yet out of favor through the 47 high quality undervalued stocks. Strengthen your income watchlist by reviewing companies in the 13 dividend fortresses that pair higher yields with a focus on resilience. Prioritize resilience by checking stocks curated in the 67 resilient stocks with low risk scores so you are not relying on Zimmer Biomet alone.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZBH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Jeff Auxier's Strategic Moves: Microsoft Corp Sees a -0.9% Portfolio Impact
May 14, 2026
This article first appeared on GuruFocus.
Insightful Analysis of Jeff Auxier (Trades, Portfolio)'s First Quarter 2026 13F Filing
Warning! GuruFocus has detected 8 Warning Signs with PM. Is PM fairly valued? Test your thesis with our free DCF calculator.
Jeff Auxier (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2026, providing insights into his investment moves during this period. Jeff Auxier (Trades, Portfolio) is the founder and CEO of Auxier Asset Management as well as the manager of the Auxier Focus Fund. The firm manages the Auxier Focus Fund as well as separate managed accounts for clients. Auxier's strategy is to look for compelling, undervalued companies that ideally exhibit the following attributes: strong or improving fundamentals, consistency in operating results, a substantial advantage over competition (strong franchise), a demonstrated ability to earn high rates of return on capital, understandable products, honest, competent and shareholder-oriented management, intelligent capital allocation policies, generates substantial free cash flow with nominal mandatory capital requirements, a strong balance sheet and financial flexibility. The investment candidates are then screened to determine what price represents good value with acceptable, low risk and the potential for above average returns.Jeff Auxier's Strategic Moves: Microsoft Corp Sees a -0.9% Portfolio Impact
Summary of New Buy
Jeff Auxier (Trades, Portfolio) added a total of 7 stocks, among them:
The most significant addition was Waters Corp (NYSE:WAT), with 2,401 shares, accounting for 0.1% of the portfolio and a total value of $715,020. The second largest addition to the portfolio was Wal-Mart de Mexico SAB de CV (WMMVY), consisting of 16,828 shares, representing approximately 0.08% of the portfolio, with a total value of $547,420. The third largest addition was Public Storage (NYSE:PSA), with 1,405 shares, accounting for 0.05% of the portfolio and a total value of $380,590.
Key Position Increases
Jeff Auxier (Trades, Portfolio) also increased stakes in a total of 38 stocks, among them:
The most notable increase was Fiserv Inc (NASDAQ:FISV), with an additional 12,500 shares, bringing the total to 60,465 shares. This adjustment represents a significant 26.06% increase in share count, a 0.1% impact on the current portfolio, with a total value of $3,373,950. The second largest increase was Zimmer Biomet Holdings Inc (NYSE:ZBH), with an additional 6,375 shares, bringing the total to 68,911. This adjustment represents a significant 10.19% increase in share count, with a total value of $6,230,930.
Story Continues
Summary of Sold Out
Jeff Auxier (Trades, Portfolio) completely exited 8 of the holdings in the first quarter of 2026, as detailed below:
Adobe Inc (NASDAQ:ADBE): Jeff Auxier (Trades, Portfolio) sold all 636 shares, resulting in a -0.03% impact on the portfolio. Builders FirstSource Inc (NYSE:BLDR): Jeff Auxier (Trades, Portfolio) liquidated all 2,000 shares, causing a -0.03% impact on the portfolio.
Key Position Reduces
Jeff Auxier (Trades, Portfolio) also reduced positions in 91 stocks. The most significant changes include:
Reduced Microsoft Corp (NASDAQ:MSFT) by 13,294 shares, resulting in a -13.53% decrease in shares and a -0.9% impact on the portfolio. The stock traded at an average price of $418.44 during the quarter and has returned 2.20% over the past 3 months and -15.19% year-to-date. Reduced Bank of New York Mellon Corp (NYSE:BK) by 30,937 shares, resulting in a -15.9% reduction in shares and a -0.51% impact on the portfolio. The stock traded at an average price of $118.92 during the quarter and has returned 15.42% over the past 3 months and 17.58% year-to-date.
Portfolio Overview
At the first quarter of 2026, Jeff Auxier (Trades, Portfolio)'s portfolio included 176 stocks, with top holdings including 4.88% in Philip Morris International Inc (NYSE:PM), 4.51% in Microsoft Corp (NASDAQ:MSFT), 3.69% in Alphabet Inc (NASDAQ:GOOGL), 3.53% in The Kroger Co (NYSE:KR), and 2.79% in Bank of New York Mellon Corp (NYSE:BK).Jeff Auxier's Strategic Moves: Microsoft Corp Sees a -0.9% Portfolio Impact
The holdings are mainly concentrated in 10 of all the 11 industries: Consumer Defensive, Financial Services, Healthcare, Technology, Consumer Cyclical, Communication Services, Energy, Industrials, Basic Materials, and Real Estate.Jeff Auxier's Strategic Moves: Microsoft Corp Sees a -0.9% Portfolio Impact
View Comments
- Can ISRG's da Vinci 5 Momentum Sustain Procedure and Utilization Gains?
May 14, 2026
Intuitive Surgical’s ISRG da Vinci 5 platform is rapidly emerging as a key growth engine, reinforcing both procedure momentum and utilization gains in the first quarter of 2026. Management highlighted that da Vinci procedures grew 16% year over year, while overall system utilization increased 4%, reflecting stronger throughput and expanding surgeon engagement. The early adoption trends suggest that da Vinci 5 may be structurally enhancing utilization rather than simply replacing prior-generation systems.
A notable differentiator is that da Vinci 5 systems are exhibiting higher utilization levels than Xi systems, even in the early phase of deployment. Management attributed this to a combination of improved surgeon ergonomics, workflow enhancements, and upgraded technology features, which are driving stronger procedural adoption among installed accounts. If sustained, this higher utilization profile could become a meaningful structural advantage, increasing recurring revenue generation per system.
Another underappreciated growth lever is after-hours procedures, which rose 31% year over year. Management noted that hospitals are increasingly using robotic systems during evenings and extended operating windows to improve asset productivity and address surgical backlogs. This trend suggests that utilization growth is being driven not only by new indications and surgeon adoption but also by more intensive use of existing systems.
The implications extend beyond procedure growth. Higher utilization strengthens the economic value proposition of robotic surgery for hospitals, which could accelerate installed base expansion, particularly for premium systems like da Vinci 5. Since Intuitive Surgical’s business model is heavily weighted toward recurring instruments, accessories and service revenues, increased utilization directly enhances revenue durability and operating leverage.
Overall, da Vinci 5 appears to be doing more than driving replacement demand — it is improving system productivity. If higher utilization trends persist, the platform could sustain above-market procedure growth while deepening Intuitive Surgical’s recurring revenue moat.
Peer Updates
Stryker SYK continues to demonstrate strong momentum in robotic surgery, though it does not provide explicit standalone procedure growth guidance for Mako. The company expects 8-9.5% organic sales growth in 2026, driven by strong procedural demand and capital placements.
Mako remains a central growth engine, with over 3,000 installed systems and rising utilization across knees and hips, where penetration continues to increase meaningfully. Key drivers for robotic procedure growth are expanding indications (shoulder, spine, advanced hips), strong capital order backlog and increasing surgeon adoption. Stryker’s strategy of continuous expansion of indications and high utilization suggests sustained double-digit robotic procedure growth.
Story Continues
Zimmer Biomet ZBH provided a more tempered 2026 outlook, guiding for 1-3% organic growth, reflecting near-term disruption rather than demand weakness. While ZBH did not provide explicit guidance on robotic procedure growth, it highlighted strong robotic capital sales and double-digit growth in its technology and data segments, indicating continued adoption of its ROSA platform.
The primary drivers for robotic procedure growth include a robust innovation cycle (like ROSA Shoulder), increased sales force specialization and deeper penetration in ambulatory service centers and underpenetrated segments. Near-term growth is constrained by U.S. sales force restructuring, with more meaningful acceleration expected beyond 2027 as productivity improves.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 23.7% so far this year compared with an 18.6% decline for the industry.Zacks Investment Research
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 39.74, above the industry average. But, it is still lower than its five-year median of 70.27. ISRG carries a Value Score of D.Zacks Investment Research
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 16.5% rise from the year-ago period’s level.Zacks Investment Research
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Jim Cramer Discusses the Performance of Danaher and Its Peers
May 14, 2026
Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said:
For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I should say a savage string of not-so-great quarters. The stock of the medical and diagnostic company is down… 27% year to date, and just head shaking, this is Danaher. Those two, of course, aren’t alone. Boston Scientific, Intuitive Surgical, Medtronic, ResMed, Stryker, Zimmer Biomet, they all hit new lows. That’s a remarkable confluence of true ugliness from some pretty darn good companies.
Photo by Adam Nowakowski on Unsplash
Danaher Corporation (NYSE:DHR) provides instruments, consumables, software, and services used in bioprocessing, life sciences research, and clinical diagnostics. Cramer mentioned the stock during the January 23 episode and commented:
CNBC Investing Club members, look out. You’re going to be flooded with emails Wednesday because Charitable Trust holdings, Danaher, Starbucks, GE Vernova, Microsoft, Meta, and Corning all report. Let me give you a preview. After a multi-year dry spell, Danaher has big orders from biotechs for expensive management. It seems like a biotech comes public every day, doesn’t it? They’ve managed some better-than-feared results in recent quarters, but this could be the first truly strong quarter in years. The stock was down badly today. Could be a real interesting opportunity.
While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- 3 Out-of-Favor Stocks We Approach with Caution
May 13, 2026
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
At StockStory, we dig beneath the surface of price movements to uncover whether a company's fundamentals justify its current valuation or suggest hidden potential. That said, here are three stocks where the skepticism is well-placed and some better opportunities to consider.
Domino's (DPZ)
One-Month Return: -12.3%
Founded by two brothers in Michigan, Domino’s (NASDAQ:DPZ) is a globally recognized pizza chain known for its creative marketing and fast delivery.
Why Is DPZ Not Exciting?
Sales trends were unexciting over the last seven years as its 5.2% annual growth was below the typical restaurant company Estimated sales growth of 6% for the next 12 months is soft and implies weaker demand
Domino's is trading at $323.50 per share, or 16.8x forward P/E. If you’re considering DPZ for your portfolio, see our FREE research report to learn more.
Zimmer Biomet (ZBH)
One-Month Return: -13.1%
With a history dating back to 1927 and a presence in over 100 countries worldwide, Zimmer Biomet (NYSE:ZBH) designs and manufactures orthopedic products including knee and hip replacements, surgical tools, and robotic technologies for joint reconstruction and spine surgeries.
Why Does ZBH Fall Short?
Sales trends were unexciting over the last two years as its 6.2% annual growth was below the typical healthcare company Estimated sales growth of 2.4% for the next 12 months implies demand will slow from its two-year trend Low returns on capital reflect management’s struggle to allocate funds effectively
Zimmer Biomet’s stock price of $82.88 implies a valuation ratio of 9.8x forward P/E. Read our free research report to see why you should think twice about including ZBH in your portfolio, it’s free.
Cogent (CCOI)
One-Month Return: -21.9%
Operating a massive network spanning 20,000 miles of fiber optic cable and connecting to over 3,200 buildings worldwide, Cogent Communications (NASDAQ:CCOI) provides high-speed Internet access, private network services, and data center colocation to businesses and bandwidth-intensive organizations across 54 countries.
Why Are We Out on CCOI?
Annual sales declines of 4.1% for the past two years show its products and services struggled to connect with the market during this cycle Diminishing returns on capital suggest its earlier profit pools are drying up Short cash runway increases the probability of a capital raise that dilutes existing shareholders
Story Continues
At $16.70 per share, Cogent trades at 9.3x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than CCOI.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
View Comments
- Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'
May 13, 2026
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
CNBC's Jim Cramer said Monday that while comparisons between today's market and the 1999 dot-com bubble are growing louder, Wall Street is punishing disappointing stocks even more aggressively than it did during that era.
"We keep hearing this drumbeat that 2026 is 1999 all over again," the "Mad Money" host said Monday on CNBC. "But the difference between now and 1999 is that this market does not stop punishing the companies that disappointed."
The comments came as the S&P 500 and Nasdaq Composite closed at record highs Monday, rising 0.19% and 0.10%, respectively.
Cramer said the broader market has become increasingly divided, with investors concentrating heavily on artificial intelligence and data center-related stocks while selling companies that miss earnings expectations or fail to impress investors.
Don't Miss:
A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and why Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast
AI Winners Vs. Market Losers
Cramer pointed to several healthcare and medical technology companies that have fallen sharply this year.
Abbott Laboratories, which narrowly missed earnings expectations, is down 34% year-to-date. Danaher Corp. has fallen 27% after what Cramer described as a "savage string of not-so-great quarters."
He also cited weakness in Boston Scientific Corp., Intuitive Surgical Inc., Medtronic PLC, ResMed Inc., Stryker Corp. and Zimmer Biomet Holdings Inc..
At the same time, Cramer said investors continue piling into AI-linked companies and data center trades because demand remains strong.
"It's like portfolio managers have decided to abandon any stocks that are not connected to AI," Cramer said.
See Also: Avoid the #1 Investing Mistake: How Your ‘Safe' Holdings Could Be Costing You Big Time
Bubble Debate Intensifies
The comments follow growing debate around whether the current AI rally resembles the late-1990s tech bubble.
Earlier this month, legendary investor Michael Burry warned that the semiconductor rally was beginning to resemble the dot-com era. Burry placed a short bet against the iShares Semiconductor ETF, which tracks major chip companies.
Cramer, however, has repeatedly defended aggressive AI and data center spending. Earlier in May, he argued strong earnings from Alphabet Inc., Amazon.com Inc. and Apple Inc. showed AI investments were producing real business results rather than signaling an unsustainable market bubble.
Story Continues
He also recently highlighted AI memory and storage companies including SanDisk Corp., Western Digital Corp. and Seagate Technology Holdings PLC as major beneficiaries of rising AI infrastructure demand.
Image via Shutterstock
Read Next:
Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier. Thinking about ETFs? See what investment risks you should be aware of before you buy.
Building Wealth Across More Than Just the Market
Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, professional financial guidance, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.
Rad AI
RAD Intel is an AI-driven marketing platform helping brands improve campaign performance by turning complex data into actionable insights for content, influencer strategy, and ROI optimization. Positioned within the multi-hundred-billion-dollar digital marketing industry, the company works with global brands across sectors to improve targeting precision and creative performance using its analytics and AI tools. With strong revenue growth, expanding enterprise contracts, and a Nasdaq ticker reserved under $RADI, RAD Intel is opening access to its Regulation A+ offering, giving investors exposure to the growing intersection of AI, marketing, and creator economy infrastructure.
Immersed
Immersed is a spatial computing company building immersive productivity software that enables users to work across multiple virtual screens inside VR and mixed-reality environments. Its platform is used by remote workers and enterprises to create virtual workspaces that reduce reliance on traditional physical hardware while improving focus and collaboration. The company is also developing its own lightweight VR headset and AI productivity tools, positioning itself in the future-of-work and spatial computing space. Through its pre-IPO offering, Immersed is opening access to early-stage investors looking to diversify beyond traditional assets and gain exposure to emerging technologies shaping how people work.
Connect Invest
Connect Invest is a real estate investment platform that allows investors to access short-term, fixed-income opportunities backed by a diversified portfolio of residential and commercial real estate loans. Through its Short Notes structure, investors can choose defined terms (6, 12, or 24 months) and earn monthly interest payments while gaining exposure to real estate as an asset class. For investors focused on diversification, Connect Invest may serve as one component within a broader portfolio that also includes traditional equities, fixed income, and other alternative assets—helping balance exposure across different risk and return profiles.
rHealth
rHealth is building a space-tested diagnostics platform designed to bring lab-quality blood testing closer to patients in minutes rather than weeks. Originally validated in collaboration with NASA for use aboard the International Space Station, the technology is now being adapted for at-home and point-of-care settings to address widespread delays in diagnostic access.
Backed by institutions including NASA and the NIH, rHealth is targeting the large global diagnostics market with a multi-test platform and a model built around devices, consumables, and software. With FDA registration in progress, the company is positioning itself as a potential shift toward faster, more decentralized healthcare testing.
Arrived
Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.
Masterworks
Masterworks enables investors to diversify into blue-chip art, an alternative asset class with historically low correlation to stocks and bonds. Through fractional ownership of museum-quality works by artists like Banksy, Basquiat, and Picasso, investors gain access without the high costs or complexities of owning art outright. With hundreds of offerings and strong historical exits on select works, Masterworks adds a scarce, globally traded asset to portfolios seeking long-term diversification.
Public
Public is a multi-asset investing platform built for long-term investors who want more control, transparency, and innovation in how they grow wealth. Founded in 2019 as the first broker-dealer to offer commission-free, real-time fractional investing, Public now lets users invest in stocks, bonds, options, crypto, and more—all in one place. Its latest feature, Generated Assets, uses AI to turn a single idea into a fully customized, investable index that can be explained and backtested before committing capital. Combined with AI-powered research tools, clear explanations of market moves, and an uncapped 1% match for transferring an existing portfolio, Public positions itself as a modern platform designed to help serious investors make more informed decisions with context.
Lightstone
Lightstone DIRECT gives accredited investors access to institutional-quality multifamily real estate opportunities backed by a vertically integrated operator with more than $12 billion in assets under management and a 40-year track record. With more than 25,000 multifamily units nationwide — including significant exposure to low-supply Midwest markets where rent growth has remained resilient — Lightstone is positioning investors to benefit from tightening housing supply, strong occupancy trends, and long-term rental demand. Through Lightstone DIRECT, individuals can co-invest alongside the firm, which commits at least 20% to each deal, offering exposure to professionally managed multifamily assets designed to generate durable income and long-term appreciation beyond the traditional stock market.
AdviserMatch
AdviserMatch is a free online tool that helps individuals connect with financial advisors based on their goals, financial situation, and investment needs. Instead of spending hours researching advisors on your own, the platform asks a few quick questions and matches you with professionals who can assist with areas like retirement planning, investment strategy, and overall financial guidance. Consultations are no-obligation, and services vary by advisor, giving investors a chance to explore whether professional advice could help improve their long-term financial plan.
Accredited Debt Relief
Accredited Debt Relief is a debt consolidation company focused on helping consumers reduce and manage unsecured debt through structured programs and personalized solutions. Having supported more than 1 million clients and helped resolve over $3 billion in debt, the company operates within the growing consumer debt relief industry, where demand continues to rise alongside record household debt levels. Its process includes a quick qualification survey, personalized program matching, and ongoing support, with eligible clients potentially reducing monthly payments by 40% or more. With industry recognition, an A+ BBB rating, and multiple customer service awards, Accredited Debt Relief positions itself as a data-driven, client-focused option for individuals seeking a more manageable path toward becoming debt-free.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View Comments
- Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
May 13, 2026 · seekingalpha.com
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- What To Expect From STERIS’s (STE) Q1 Earnings
May 13, 2026
Medical equipment and services company Steris (NYSE:STE). will be reporting results this Monday after the bell. Here’s what you need to know.
STERIS beat analysts’ revenue expectations last quarter, reporting revenues of $1.50 billion, up 9.2% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ revenue estimates.
Is STERIS a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting STERIS’s revenue to grow 7.7% year on year, improving from the 4.3% increase it recorded in the same quarter last year.STERIS Total Revenue
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. STERIS has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at STERIS’s peers in the surgical equipment & consumables - diversified segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Zimmer Biomet delivered year-on-year revenue growth of 9.3%, beating analysts’ expectations by 0.9%, and CONMED reported a revenue decline of 1.3%, topping estimates by 2.1%. Zimmer Biomet traded down 13.5% following the results while CONMED was up 1.9%.
Read our full analysis of Zimmer Biomet’s results here and CONMED’s results here.
There has been positive sentiment among investors in the surgical equipment & consumables - diversified segment, with share prices up 6.1% on average over the last month. STERIS is down 8.2% during the same time and is heading into earnings with an average analyst price target of $279.29 (compared to the current share price of $204.28).
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
View Comments
- Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
May 12, 2026
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption.(PRNewsfoto/Zimmer Biomet Holdings, Inc.)
All repurchases are expected to be made under the company's existing $1.5 billion share repurchase authorization, which was approved by the Zimmer Biomet Board of Directors and announced in February 2026. The company has not made any changes to the size, duration or terms of that authorization.
The company may repurchase shares in the open market and/or enter into structured repurchase agreements with third parties. The timing and actual amount of share repurchases will depend on a variety of considerations, including market conditions, the company's stock price, capital availability and alternative uses of capital.
About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, statements regarding macro pressures, including the impact of such pressures on our business, and any statements about our forecasts, expectations, plans, intentions, commitments, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: competition; pricing pressures; dependence on new product development, technological advances and innovation; changes in customer demand for our products and services caused by demographic changes, obsolescence, development of different therapies or other factors; our ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business; the transformation of our sales and distribution network in the U.S. and other markets; challenges relating to the rationalization of our products; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; the risks and uncertainties relating to our ability to successfully execute on our product portfolio rationalization plans; control of costs and expenses; risks related to the ability to realize the anticipated benefits of our acquisitions, including the possibility that the expected benefits from such transactions will not be realized or will not be realized within the expected time period; the risk that acquired businesses will not be integrated successfully; the effects of business disruptions affecting us, our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully integrate the operations, products, service providers, agents, employees, sales representatives and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; breaches or failures of our (or of our business partners' or other third parties') information technology systems or products, including by cyberattack, unauthorized access or theft; the outcome of government investigations; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise; the effects of natural disasters, or of legal, regulatory or market measures to address natural disasters; the effects of our commitments, goals and disclosures relating to corporate responsibility matters; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the "base erosion and profit shifting" project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc.; the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees; changes in tariffs relating to imports to the U.S. and other countries; the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates; the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws; the success of our quality and operational excellence initiatives; the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.
Story Continues
Contacts: Media
Troy Kirkpatrick
614-284-1926
troy.kirkpatrick@zimmerbiomet.com Investors
David DeMartino
646-531-6115
david.demartino@zimmerbiomet.com Kirsten Fallon
781-779-5561
kirsten.fallon@zimmerbiomet.com Zach Weiner
908-591-6955
zach.weiner@zimmerbiomet.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-increases-share-repurchase-expectations--up-to-1-billion-by-year-end-302768940.html
View Comments
- Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
May 12, 2026 · prnewswire.com
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption.
